These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 3740944)

  • 1. Behçet's syndrome: treatment with recombinant leukocyte alpha-interferon.
    Tsambaos D; Eichelberg D; Goos M
    Arch Dermatol Res; 1986; 278(4):335-6. PubMed ID: 3740944
    [No Abstract]   [Full Text] [Related]  

  • 2. [Behçet disease and exogenous interferon. A successful treatment study using recombinant alpha-A-IFN].
    Stadler R; Bratzke B; Baumann I
    Hautarzt; 1987 Feb; 38(2):97-100. PubMed ID: 3570783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [New therapeutic prospectives in Behçet's disease: beta-interferon].
    Tata F; Gori E; De Bartolomeis AM; Mari MV
    Recenti Prog Med; 1988 Mar; 79(3):135-7. PubMed ID: 3393721
    [No Abstract]   [Full Text] [Related]  

  • 4. Topical alpha interferon in the treatment of oral ulcers in Behçet's syndrome: a preliminary report.
    Hamuryudan V; Yurdakul S; Serdaroglu S; Tüzün Y; Rosenkaimer F; Yazici H
    Clin Exp Rheumatol; 1990; 8(1):51-4. PubMed ID: 2189624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Therapeutic use of alpha interferon in metastasizing malignant melanoma, disseminated Kaposi sarcoma and severe Behçet disease].
    Stadler R; Bratzke B; Orfanos CE
    Hautarzt; 1987 Aug; 38(8):453-60. PubMed ID: 3654216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inefficacy of topical alpha interferon in the treatment of oral ulcers of Behçet's syndrome: a randomized, double blind trial.
    Hamuryudan V; Yurdakul S; Rosenkaimer F; Yazici H
    Br J Rheumatol; 1991 Oct; 30(5):395-6. PubMed ID: 1913022
    [No Abstract]   [Full Text] [Related]  

  • 7. Beneficial effects of interferon-alpha in a case with Behçet's disease.
    Aoki T; Tanaka T; Akifuji Y; Ueki J; Nakamura I; Nemoto R; Ito K
    Intern Med; 2000 Aug; 39(8):667-9. PubMed ID: 10939544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon therapy in Behçet's disease.
    Sakane T; Takene M
    Intern Med; 2000 Aug; 39(8):604-5. PubMed ID: 10939531
    [No Abstract]   [Full Text] [Related]  

  • 9. Interferon-alpha 2b for refractory ocular Behçet's disease.
    Feron EJ; Rothova A; van Hagen PM; Baarsma GS; Suttorp-Schulten MS
    Lancet; 1994 Jun; 343(8910):1428. PubMed ID: 7910903
    [No Abstract]   [Full Text] [Related]  

  • 10. Interferon-alpha 2b for refractory ocular Behçet's disease.
    Durand JM; Soubeyrand J
    Lancet; 1994 Jul; 344(8918):333. PubMed ID: 7914275
    [No Abstract]   [Full Text] [Related]  

  • 11. Interferon alfa-2a in the treatment of Behçet's disease.
    Azizlerli G; Sarica R; Köse A; Ovül C; Kavala M; Kayabali M; Erkan F; Kural Z
    Dermatology; 1996; 192(3):239-41. PubMed ID: 8726638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Interferon and Behcet's disease. Therapeutic exception or loss of chance?].
    Wechsler B
    Rev Med Interne; 2000 Sep; 21(9):745-6. PubMed ID: 11039169
    [No Abstract]   [Full Text] [Related]  

  • 13. Interferon therapy for Behçet's disease.
    Alpsoy E; Yilmaz E; Başaran E
    J Am Acad Dermatol; 1994 Oct; 31(4):617-9. PubMed ID: 8089288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Behçet's syndrome: treatment with recombinant interferon gamma].
    Kirch W; Dührsen U
    Dtsch Med Wochenschr; 1990 Mar; 115(9):357. PubMed ID: 2106427
    [No Abstract]   [Full Text] [Related]  

  • 15. [Behçet's disease: therapy with recombinant interferon gamma].
    Fierlbeck G
    Dtsch Med Wochenschr; 1989 Nov; 114(45):1769. PubMed ID: 2509188
    [No Abstract]   [Full Text] [Related]  

  • 16. Treatment of Adamantiades-Behçet disease with systemic interferon alfa.
    Zouboulis CC; Orfanos CE
    Arch Dermatol; 1998 Aug; 134(8):1010-6. PubMed ID: 9722733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Adamantiades-Behçet disease. Therapeutic administration of systemic recombinant interferon-alpha-2a].
    Zouboulis CC; Treudler R; Orfanos CE
    Hautarzt; 1993 Jul; 44(7):440-5. PubMed ID: 8365878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Behçet's disease--clinical presentation, diagnostic and therapeutic approach].
    Elbirt D; Asher I; Sthoeger ZM
    Harefuah; 2002 May; 141(5):462-7, 497. PubMed ID: 12073530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic interferon alpha 2b treatment in Behçet's syndrome.
    Hamuryudan V; Moral F; Yurdakul S; Mat C; Tüzün Y; Ozyazgan Y; Direskeneli H; Akoglu T; Yazici H
    J Rheumatol; 1994 Jun; 21(6):1098-100. PubMed ID: 7932420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Behçet's syndrome: pathogenesis, diagnosis, and treatment.
    Jorizzo JL
    Cutis; 1983 Nov; 32(5):441-5, 448. PubMed ID: 6653169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.